Here are the latest quarterly results of Dr. Reddys. For more details, see the Dr. Reddys financial fact sheet and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 38,646 | 40,296 | 38,582 | 48,128 | 43,971 | 44,489 | 44,265 | 49,109 | |
Other income | Rs m | 1,023 | 833 | 4,301 | 540 | 673 | 736 | 871 | 512 | |
Turnover | Rs m | 39,669 | 41,129 | 42,883 | 48,668 | 44,644 | 45,225 | 45,136 | 49,621 | |
Expenses | Rs m | 30,600 | 32,107 | 31,165 | 37,490 | 46,858 | 34,997 | 33,052 | 37,548 | |
Gross profit | Rs m | 8,046 | 8,189 | 7,417 | 10,638 | -2,887 | 9,492 | 11,213 | 11,561 | |
Depreciation | Rs m | 2,903 | 2,872 | 2,890 | 3,131 | 2,869 | 2,741 | 2,923 | 3,165 | |
Interest | Rs m | 241 | 245 | 298 | 303 | 152 | 230 | 233 | 252 | |
Profit before tax | Rs m | 5,925 | 5,905 | 8,530 | 7,744 | -5,235 | 7,257 | 8,928 | 8,656 | |
Tax | Rs m | 1,011 | 1,508 | 1,928 | -3,207 | 325 | -449 | 3,059 | 1,011 | |
Profit after tax | Rs m | 4,914 | 4,397 | 6,602 | 10,951 | -5,560 | 7,706 | 5,869 | 7,645 | |
Gross profit margin | % | 20.8 | 20.3 | 19.2 | 22.1 | -6.6 | 21.3 | 25.3 | 23.5 | |
Effective tax rate | % | 17.1 | 25.5 | 22.6 | -41.4 | -6.2 | -6.2 | 34.3 | 11.7 | |
Net profit margin | % | 12.7 | 10.9 | 17.1 | 22.8 | -12.6 | 17.3 | 13.3 | 15.6 | |
Diluted EPS | Rs | 29.7 | 26.5 | 39.8 | 66.1 | -33.6 | 46.5 | 35.4 | 46.1 | |
Diluted EPS (TTM) | Rs | 105.4 | 115.5 | 126.6 | 162.1 | 98.9 | 118.9 | 114.5 | 94.5 | |
![]() |
Read: Dr. Reddys 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SANOFI INDIA ORCHID PHARMA GSK PHARMA SUVEN LIFE SCIENCES NOVARTIS
Compare DR. REDDYS LAB With: SANOFI INDIA ORCHID PHARMA GSK PHARMA SUVEN LIFE SCIENCES NOVARTIS
Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More